RU94023600A - METHOD FOR TREATING HEMOCHROMATOSIS - Google Patents

METHOD FOR TREATING HEMOCHROMATOSIS

Info

Publication number
RU94023600A
RU94023600A RU94023600/14A RU94023600A RU94023600A RU 94023600 A RU94023600 A RU 94023600A RU 94023600/14 A RU94023600/14 A RU 94023600/14A RU 94023600 A RU94023600 A RU 94023600A RU 94023600 A RU94023600 A RU 94023600A
Authority
RU
Russia
Prior art keywords
hemochromatosis
olyphene
daily dose
treating
treatment
Prior art date
Application number
RU94023600/14A
Other languages
Russian (ru)
Other versions
RU2078567C1 (en
Inventor
С.П. Щербинина
Ю.В. Медведев
Л.А. Жеребцов
А.А. Левина
В.Р. Акоев
Т.Г. Сарычева
В.Н. Рудакова
Т.В. Пенкина
А.Т. Годжаева
Original Assignee
Гематологический научный центр РАМН
Filing date
Publication date
Application filed by Гематологический научный центр РАМН filed Critical Гематологический научный центр РАМН
Priority to RU94023600A priority Critical patent/RU2078567C1/en
Priority claimed from RU94023600A external-priority patent/RU2078567C1/en
Application granted granted Critical
Publication of RU2078567C1 publication Critical patent/RU2078567C1/en
Publication of RU94023600A publication Critical patent/RU94023600A/en

Links

Claims (5)

1. Способ лечения гемохроматоза фармацевтическими препаратами в виде монотерапии или на фоне симптоматической терапии, отличающийся тем, что в качестве фармацевтического препарата используется "Олифен".1. A method of treating hemochromatosis with pharmaceutical preparations in the form of monotherapy or against the background of symptomatic therapy, characterized in that "Olifen" is used as a pharmaceutical preparation. 2. Способ по п. 1, отличающийся тем, что "Олифен" вводят внутривенно в виде инфузии, суточная доза составляет 2 мл 7%-ного раствора однократно. 2. The method according to p. 1, characterized in that "Olyphene" is administered intravenously as an infusion, the daily dose is 2 ml of a 7% solution once. 3. Способ по п. 1, отличающийся тем, что "Олифен" больные принимают перорально, суточная доза составляет 1,5 - 2,0 г. 3. The method according to p. 1, characterized in that "Olyphenum" patients take orally, the daily dose is 1.5 - 2.0 g. 4. Способ по п. 1, отличающийся тем, что лечение проводят сочетанием внутривенного и перорального введения препарата "Олифен". 4. The method according to p. 1, characterized in that the treatment is carried out by a combination of intravenous and oral administration of the drug "Olyphene". 5. Способ по п. 1, отличающийся тем, что длительность курса лечения зависит от клинической стадии гемохроматоза и наличия сопутствующих заболеваний. 5. The method according to p. 1, characterized in that the duration of the course of treatment depends on the clinical stage of hemochromatosis and the presence of concomitant diseases.
RU94023600A 1994-06-22 1994-06-22 Method of hemochromatosis treatment RU2078567C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94023600A RU2078567C1 (en) 1994-06-22 1994-06-22 Method of hemochromatosis treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94023600A RU2078567C1 (en) 1994-06-22 1994-06-22 Method of hemochromatosis treatment

Publications (2)

Publication Number Publication Date
RU2078567C1 RU2078567C1 (en) 1997-05-10
RU94023600A true RU94023600A (en) 1997-11-10

Family

ID=20157539

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94023600A RU2078567C1 (en) 1994-06-22 1994-06-22 Method of hemochromatosis treatment

Country Status (1)

Country Link
RU (1) RU2078567C1 (en)

Similar Documents

Publication Publication Date Title
JPH0222229A (en) Combination preparation used in treatment of disease or injury of nerve cell and nerve fiber
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
US4435449A (en) Treatment of minimal brain dysfunction (MBD)
RU96122884A (en) HUMAN CANCER TREATMENT METHOD
RU94022479A (en) Use of antiestrogenic compounds and pharmaceutically acceptable salts and solvents for blood glucose concentration decrease, pharmaceutical preparation
RU95101385A (en) Products containing g-csf and tnf-binding protein
RU2001118854A (en) OPTICALLY ACTIVE DERIVATIVE OF Pyridyl-4H-1,2,4-Oxadiazine AND ITS APPLICATION FOR TREATMENT OF VASCULAR DISEASES
JPH01261334A (en) Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof
RU94023600A (en) METHOD FOR TREATING HEMOCHROMATOSIS
RU2002129298A (en) APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE
RU2003100081A (en) METHODS AND COMPOSITIONS IN WHICH SULODEXIDE IS USED FOR THE TREATMENT OF DIABETIC NEPHROPATHY
RU95112520A (en) APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS
CA2368352A1 (en) Method for treating neurodegeneration
JPH0251405B2 (en)
SU429813A1 (en) METHOD OF TREATING PULMONARY TUBERCULOSIS
SU1169655A1 (en) Method of treatment of thrombolytic diseases of the artery of the extremities
US5081129A (en) Method of treatment of anemia with seratonin antagonists
RU2132188C1 (en) Method of treating thyroid gland hypofunction
KR960014873B1 (en) Pharmaceutical compositions for alleviation of panic disorders containing gepirone
JPS6041052B2 (en) psychotropic drugs
SU1034741A1 (en) Tuberculosis treatment method
RU1803119C (en) Method of extrauterine pregnancy treatment
Melina et al. Antihypertensive effect of nimodipine in elderly patients with chronic cerebrovascular disease: A preliminary report.
US4742076A (en) Etodolac for lowering rheumatoid factor
Berman et al. Hemodialysis-associated infections: treatment with cephapirin